Moderna chasing ‘holy grail’ of cancer prevention
Moderna CEO Stéphane Bancel says the company's personalized mRNA cancer vaccine could work in "more cancers than melanoma" and aims for FDA approval by 2027, with shares up 750% in 2026.
20 trends tracked about this subject — the full history, oldest to newest below.
Moderna CEO Stéphane Bancel says the company's personalized mRNA cancer vaccine could work in "more cancers than melanoma" and aims for FDA approval by 2027, with shares up 750% in 2026.
Moderna swings to a profit as momentum builds for its cancer vaccine, according to financial reports.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
A landmark trial reveals the first successful cancer vaccine, reducing the risk of melanoma recurrence or death by 42%.
Moderna's cancer vaccine shows a 42% reduction in melanoma recurrence in Phase 3 trial data leaked prior to ESMO.
A personalized mRNA cancer vaccine developed by Moderna and Merck cuts melanoma recurrence or death risk by 42%.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Personalized mRNA cancer vaccine data shows significant reduction in melanoma recurrence and death rates.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
14 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Moderna and Merck trial data sparks debate over whether a personalized medicine revolution is beginning.
BioNTech and Genentech have terminated a phase 2 mRNA colorectal cancer vaccine trial after safety reviews revealed more deaths than in the control group.
Analysts are closely monitoring the impact of intismeran following a landmark Phase III clinical trial victory in the cancer vaccine sector.
Moderna and Merck have reported a significant triumph regarding a collaborative cancer vaccine trial that could revolutionize oncology treatment.
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Moderna and Merck report success in a late-stage melanoma trial for their personalized mRNA cancer vaccine.
Scientific testing is currently underway on new vaccines designed to intercept hereditary colon and pancreatic cancers.